Advertisement

Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study

      Abstract

      Background

      Plasma concentrations of atrial and brain natriuretic peptides (ANP, BNP), of their N-terminal pro-peptides, of endothelin-1 (ET-1), and big endothelin-1 (big ET-1) have diagnostic and prognostic significance in congestive heart failure (CHF). However, their respective values as a predictor of survival remain controversial and have never been directly compared in severe CHF.

      Methods and results

      We analyzed, in 47 patients with severe CHF (New York Heart Association [NYHA] class III to IV; age 66 ± 8 years, ejection fraction 20 ± 6%), the prognostic performance of a panel of neurohormones and assays (N-terminal pro-ANP 1-25, 68-98 by radioimmunoassay [RIA], and 1-98 by enzyme-linked immunosorbent assay [ELISA], BNP by RIA and immunoradiometric assay [IRMA], N-terminal pro-BNP by Elisa, ET-1 by RIA, and big ET-1 by RIA and Elisa. Data were compared with 40 patients with mild to moderate CHF [NYHA I-II] and 30 healthy subjects. After a follow-up of 81 ± 15 months, there were 34 deaths and 1 heart transplant. All neurohormones were significantly higher at baseline in patients with severe than in mild to moderate CHF or healthy subjects (all P < .001). Although all neurohormones but BNP IRMA were significant predictors of survival in univariate analysis, only big ET-1 RIA and ET-1 were independent predictors of survival (improvement χ2: 7.5 and 4.6, P < .01 and P < .05). Using medians as cutpoints of big ET-1 RIA and ET-1, 2 severe CHF populations were defined with a different outcome (5-year survival: 55 versus 18%, P < .01).

      Conclusions

      Big ET-1 and ET-1 are strong independent predictors of survival in patients with severe CHF and better for this purpose than natriuretic peptides or their pro-peptides. These markers allow easily to identify a population with a very high risk mortality eligible for more aggressive therapies.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Francis G.S.
        • Benedict C.
        • Johnstone D.E.
        • Kirlin P.C.
        • Nicklas J.
        • Liang C.S.
        • for the SOLVD Investigators
        • et al.
        Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure.
        Circulation. 1990; 82: 1724-1729
        • Swedberg K.
        • Eneroth P.
        • Kjekshus J.
        • Wilhelmsen L.
        • for the CONSENSUS Trial Study Group
        Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality.
        Circulation. 1990; 82: 1730-1736
        • Rouleau J.L.
        • Packer M.
        • Moye L.
        • de Champlain J.
        • Bichet D.
        • Klein M.
        Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
        J Am Coll Cardiol. 1994; 24: 583-591
        • Hall C.
        • Rouleau J.L.
        • Moye L.
        • de Champlain J.
        • Bichet D.
        • Klein M.
        N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction.
        Circulation. 1994; 89: 1934-1942
        • Omland T.
        • Aakvaag A.
        • Bonarjee V.S.S.
        • Caidahl K.
        • Lie R.T.
        • Nilsen D.W.T.
        • et al.
        Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide.
        Circulation. 1996; 93: 1963-1969
        • Selvais P.L.
        • Robert A.
        • Ahn S.
        • Van Linden F.
        • Ketelslegers J.M.
        • Pouleur H.
        • et al.
        Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure.
        J Card Fail. 2000; 6: 201-207
        • Richards A.M.
        • Nicholls M.G.
        • Yandle T.G.
        • Frampton C.
        • Espiner E.A.
        • Turner J.G.
        • et al.
        Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction.
        Circulation. 1998; 97: 1921-1929
        • Maeda K.
        • Tsutamoto T.
        • Wada A.
        • Mabuchi N.
        • Hayashi M.
        • Tsutsui T.
        • et al.
        High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.
        J Am Coll Cardiol. 2000; 36: 1587-1593
        • Wei C.-M.
        • Lerman A.
        • Rodeheffer R.J.
        • McGregor C.G.
        • Brandt R.R.
        • Wright S.
        • et al.
        Endothelin in human congestive heart failure.
        Circulation. 1994; 89: 1580-1586
        • Sakai S.
        • Miyauchi T.
        • Kobyashi M.
        • Yamaguchi I.
        • Goto K.
        • Sugishita Y.
        Inhibition of myocardial endothelin pathways improves long-term survival in heart failure.
        Nature. 1996; 384: 353-355
        • Pacher R.
        • Stanek B.
        • Hülsmann M.
        • Koller-Strametz J.
        • Berger R.
        • Schuller M.
        • et al.
        Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure.
        J Am Coll Cardiol. 1996; 27: 633-641
        • Pousset F.
        • Isnard R.
        • Lechat P.
        • Kalotka H.
        • Carayon A.
        • Maistre G.
        • et al.
        Prognostic value of plasma endothelin-1 in patients with chronic heart failure.
        Eur Heart J. 1997; 18: 254-258
        • Stanek B.
        • Frey B.
        • Hülsmann M.
        • Koller-Strametz J.
        • Hartter E.
        • Schuller M.
        • et al.
        Validation of big endothelin plasma levels compared with established neurohumoral markers in patients with severe chronic heart failure.
        Transplant Proc. 1997; 29: 595-596
        • Rousseau M.F.
        • Gurné O.
        • Duprez D.
        • Van Mieghem W.
        • Robert A.
        • Ahn S.
        • et al.
        Beneficial neurohormonal profile of Spironolactone in severe congestive heart failure. Results from the RALES neurohormonal substudy.
        J Am Coll Cardiol. 2002; 40: 1596-1601
        • Pitt B.
        • Zannad F.
        • Remme J.
        • Cody R.
        • Castaigne A.
        • Perez A.
        • et al.
        The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
        N Engl J Med. 1999; 341: 709-717
        • Packer M.
        • Coats A.J.S.
        • Fowler M.B.
        • Katus H.A.
        • Krum H.
        • Mohacsi P.
        • for the Carvedilol Prospective Randomized Cumulative Survival Study Group
        • et al.
        Effect of carvedilol on survival in severe chronic heart failure.
        N Engl J Med. 2001; 344: 1651-1658
        • Aaronson K.D.
        • Schwartz J.S.
        • Chen T.-M.
        • Wong K.-L.
        • Goin J.E.
        • Mancini D.M.
        • et al.
        Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation.
        Circulation. 1997; 95: 2660-2667
        • Hülsmann M.
        • Stanek B.
        • Frey B.
        • Sturm B.
        • Putz D.
        • Kos T.
        • et al.
        Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure.
        J Am Coll Cardiol. 1998; 32: 1695-1700
        • Glantz S.
        • Slinker B.
        Applied regression and analysis of variance.
        McGraw Hill Inc, New York2001 (p. 949)
        • Tsutamato T.
        • Wada A.
        • Hisanaga T.
        • Maeda K.
        • Ohnishi M.
        • Mabuchi N.
        • et al.
        Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure.
        J Am Coll Cardiol. 1999; 33: 530-537
        • Kaufman H.
        • Oribe E.
        • Olivier J.E.
        Plasma endothelin during upright tilt: relevance for orthostatic hypertension?.
        Lancet. 1991; 338: 1542-1545
        • Dupuis J.
        • Stewart D.J.
        • Cernacek P.
        • Gosselin G.
        Human pulmonary circulation is an important site for both clearance and production of endothelin-1.
        Circulation. 1996; 94: 1578-1584
        • Dupuis J.
        • Rouleau J.L.
        • Cernacek P.
        Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction.
        Circulation. 1998; 98: 1684-1687
        • Stanek B.
        • Frey B.
        • Hülsmann M.
        • Berger R.
        • Sturm B.
        • Strametz-Juranek J.
        • et al.
        Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.
        J Am Coll Cardiol. 2001; 38: 436-442
        • Berger R.
        • Hülsmann M.
        • Strecker K.
        • Bojic A.
        • Moser P.
        • Stanek B.
        • et al.
        B-type natriuretic peptide predicts sudden death in patients chronic heart failure.
        Circulation. 2002; 105: 2392-2397
        • Tsutamoto T.
        • Wada A.
        • Maeda K.
        • Hisanaga T.
        • Maeda Y.
        • Fukai D.
        • et al.
        Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.
        Circulation. 1997; 96: 509-516
        • Selvais P.L.
        • Donckier J.E.
        • Robert A.
        • Laloux O.
        • Van Linden F.
        • Ahn S.
        • et al.
        Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influence of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation.
        Eur J Clin Invest. 1998; 28: 636-642
        • Packer M.
        Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure?.
        Circulation. 2003; 108: 2950-2953
        • Maeda K.
        • Takayoshi T.
        • Wada A.
        • Hisanagra T.
        • Kinoshita M.
        Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction.
        Am Heart J. 1998; 135: 825-832
        • Frühwald F.M.
        • Fahrleitner A.
        • Watzinger N.
        • Dobnig H.
        • Schumacher M.
        • Maier R.
        • et al.
        N-terminal proatrial natriuretic peptide correlates with systolic dysfunction and left ventricular filling pattern in patients with idiopathic cardiomyopathy.
        Heart. 1999; 82: 630-633